Solid lipid nanoparticles: Production, characterization and applications

Advanced Drug Delivery Reviews

Volumn 64, Issue SUPPL., 2012, Pages 83-101

  Mehnert, Wolfgang ^a   Mäder, Karsten ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Administration routes; Coexistence of different colloidal species; Colloidal drug carriers; Drug incorporation; Production parameters; SLN quality and structure; Stability

Indexed keywords

ALTERNATIVE STRUCTURE; ANALYTICAL METHOD; COEXISTENCE OF DIFFERENT COLLOIDAL SPECIES; COLLOIDAL DRUG CARRIERS; COLLOIDAL STRUCTURES; DRUG INCORPORATION; DYNAMIC PHENOMENA; IN-VIVO; LIPID MODIFICATIONS; MIXED MICELLES; MOLECULAR LEVELS; NANO-SUSPENSIONS; PHYSICAL STATE; PRODUCTION PARAMETERS; SOLID LIPID NANOPARTICLE (SLN); SUPERCOOLED MELT;

CONVERGENCE OF NUMERICAL METHODS; LIPOSOMES; LIQUID CRYSTALS; MICELLES; SPRAY DRYING; STABILIZATION;

NANOPARTICLES;

ACICLOVIR; ALPHA TOCOPHEROL; BETAMETHASONE VALERATE; CAMPTOTHECIN; CORTISONE; CYCLOSPORIN; DIAZEPAM; DOXORUBICIN; DRUG CARRIER; ETOMIDATE; GADOLINIUM; HYDROCORTISONE; IDARUBICIN; LIPID; LIPOFUNDIN; LIPOSOME; MENADIONE; OXAZEPAM; PILOCARPINE; POLOXAMER; PROGESTERONE; RETINOL; SOLID LIPID NANOPARTICLE; TETRACAINE; THYMOPENTIN; TIMOLOL; TOCOPHEROL; TYLOXAPOL; UBIDECARENONE; UNINDEXED DRUG;

ANALYTIC METHOD; COLLOID; DISPERSION; DRUG RELEASE; FREEZE DRYING; HUMAN; IN VIVO STUDY; LIQUID CRYSTAL; MOLECULAR STABILITY; NANOSUSPENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPRAY DRYING; SUSPENSION;

EID: 84870252557     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.021     Document Type: Review

References (195)

1. Sandow J., Streckemann K., Jerabek-Sandow G. Pharmacokinetics and endocrine effects of slow release formulation of LHRH analogues. J. Steroid Biochem. Mol. Biol. 1990, 37:925-931.
2. Sipos E.P., Tyler B., Piantadosi S., Burger P.C., Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol. 1997, 39:383-389.
3. Müller B.G., Leuenberger H., Kissel T. Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm. Res. 1996, 13:32-37.
4. Scheffel U., Rhodes B.A., Natajaran T.K., Wagner H.N. Albumin microspheres for study of the reticuloendothelial system. J. Nucl. Med. 1970, 13:498-503.
5. Allémann E., Gurny R., Doelker E. Drug loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 1993, 39:173-191.
6. Kopecek J., Kopecková P., Minko T. HPMA copolymer-bound anticancer drugs: mechanism of action on cellular and subcellular levels. Proc. Int. Symp. Controlled Rel. Bioact. Mater. 1999, 26:24-25.
7. Al-Khouri-Fallouh N., Roblot-Treupel L., Fessi H., Devissaguet J.P., Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int. J. Pharm. 1986, 28:125-132.
8. Damge C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as carriers for oral peptide delivery. J. Controlled Rel. 1990, 13:233-239.
9. Smith A., Hunneyball I.M. Evaluation of polylactid as a biodegradable drug delivery system for parenteral administration. Int. J. Pharm. 1986, 30:215-230.
10. Liposome Technology 1984, CRC Press Inc, Boca Raton. G. Gregoriadis (Ed.).
11. Liposomes in Drug Delivery 1993, Harwood Academic Publishers, Amsterdam. G. Gregoriadis, A.T. Florence, H.M. Patel (Eds.).
12. Senior J.H. Fate and behaviour of liposomes in vivo. A review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3:123-193.
13. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113:171-199.
14. Crommelin D.J.A., Schreier H. Liposomes. Colloidal Drug Delivery Systems 1994, 73-190. Marcel Dekker Inc, New York, Basel, Hong Kong. J. Kreuter (Ed.).
15. Huang S.K., Mayhew E., Gilani S., Lasic D.D., Martin F.J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-12 colon carcinoma. Cancer Res. 1992, 52:6774-6781.
16. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
17. Torchilin V.P. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 1985, 2:65-115.
18. Senior J.H., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
19. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
20. Martin F., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. J. Biol. Chem. 1982, 257:286-288.
21. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 1994, 15:215-220.
22. Janknecht R., De Marie S., Bakker-Woudenberg I.A.J.M., Crommelin D.J.A. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 1992, 23:279-291.
23. Couvreur P., Dubernet C., Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 1995, 41:2-13.
24. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J.M., Pugh S., Polin L., Jones J., Corbett T., Cooper E., Liversidge G.G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 1996, 13:272-278.
25. Müller R.H., Peters K. Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int. J. Pharm. 1998, 160:229-237.
26. Ford J., Woolfe J., Florence A.T. Nanospheres of cyclosporin A: poor oral absorption in dogs. Int. J. Pharm. 1999, 183:3-6.
27. Wretlind A. Development of fat emulsions. J. Parenter. Enter. Nutr. 1981, 5:230-235.
28. Collins-Gold L.C., Lyons R.T., Bartholow L.C. Parenteral emulsions for drug delivery. Adv. Drug. Deliv. Rev. 1990, 5:189-208.
29. Prankerd R.J., Stella V.J. The use of oil-in-water emulsions as a vehicle for parenteral drug administration. J. Parent. Sci. Technol. 1990, 44:139-149.
30. Venkataram S., Awni W.M., Jordan K., Rahman Y.E. Pharmacokinetics of two alternative dosage forms for cyclosporine: Liposomes and Intralipid. J. Pharm. Sci. 1990, 79:216-219.
31. Davis S.S. Pharmaceutical aspects of intravenous fat emulsions. Am. J. Hosp. Pharm. 1974, 31:149-170.
32. Davis S.S. The emulsion-obsolete dosage form or novel drug delivery system and therapeutic agent?. J. Clin. Pharm. 1976, 1:11-27.
33. Elbaz E., Zeevi A., Klang S., Benita S. Positively charged submicron emulsions - a new type of colloidal drug carrier. Int. J. Pharm. 1993, 96:R1-R6.
34. Müller R.H., Heinemann S. Fat emulsions for parenteral nutrition IV: Lipofundin MCT/LCT regimens for total parenteral nutrition (TPN) with high electrolyte load. Int. J. Pharm. 1994, 107:121-132.
35. Klang S.H., Parnas M., Benita S. Emulsions as drug carriers - possibilities, limitations and future perspectives. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs 1998, 31-65. Medpharm Scientific Publishers, Stuttgart. R.H. Müller, S. Benita, B. Böhm (Eds.).
36. Davis S.S., Washington C., West P., Illum L. Lipid emulsions as drug delivery systems. Ann. N.Y. Acad. Sci. 1987, 507:75-88.
37. Graham C.W., Pagano R.R., Katz R.L. Thrombophlebitis after intravenous diazepam - can it be prevented. Anesth. Analg. 1977, 56:409-413.
38. Levy M.Y., Benita S. Design and characterization of a submicronized o/w emulsion of diazepam for parenteral use. Int. J. Pharm. 1989, 54:103-112.
39. Jumaa M., Müller B.W. Lipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: mechanism of the protective effect. Eur. J. Pharm. Sci. 2000, 9:285-290.
40. Magenheim B., Levy M.Y., Benita S. A new in vitro technique for evaluation of drug release profile from colloidal carriers - ultrafiltration technique at low pressure. Int. J. Pharm. 1993, 94:115-123.
41. Benita S., Friedmann D., Weinstock M. Pharmacological evaluation of an injectable prolonged release emulsion of physiostigmine in rabbits. J. Pharm. Pharmacol. 1986, 38:653-658.
42. Benita S., Friedmann D., Weinstock M. Physiostigmine emulsions: a new injectable controlled release delivery system. Int. J. Pharm. 1986, 30:47-55.
43. Nishikawa M., Takakura Y., Hashida M. Biofate of fat emulsions. Submicron Emulsions in Drug Targeting and Delivery 1998, 99-118. Harwood Academic Publishers, Amsterdam. S. Benita (Ed.).
44. Eldem T., Speiser P., Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm. Res. 1991, 8:47-54.
45. P. Speiser, Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung, European Patent EP 0167825, 1990.
46. A.J. Domb, Lipospheres for controlled delivery of substances, United States Patent, 1993, USS 188837.
47. Domb A.J. Long acting injectable oxytetracycline-liposphere formulation. Int. J. Pharm. 1995, 124:271-278.
48. Domb A.J. Liposphere parenteral delivery system. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1993, 20:346-347.
49. Siekmann B., Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1992, 1:123-126.
50. R.H. Müller, J.S. Lucks, Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN), European Patent No. 0605497, 1996.
51. Müller R.H., Mehnert W., Lucks J.S., Schwarz C., Zur Mühlen A., Weyhers H., Freitas C., Rühl D. Solid lipid nanoparticles (SLN) - An alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 1995, 41:62-69.
52. Sjöström B., Bergenståhl B. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions. I. Model studies of the precipitation of cholesteryl acetate. Int. J. Pharm. 1992, 88:53-62.
53. Cavalli R., Caputo O., Gasco M.R. Solid lipospheres of doxorubicin and idarubicin. Int. J. Pharm. 1993, 89:R9-R12.
54. M.R. Gasco, Method for producing solid lipid microspheres having a narrow size distribution. United States Patent, 1993, USS 188837.
55. Müller R.H., Runge S.A. Solid lipid nanoparticles (SLN®) for controlled drug delivery. Submicron Emulsions in Drug Targeting and Delivery 1998, 219-234. Harwood Academic Publishers, Amsterdam. S. Benita (Ed.).
56. Ahlin P., Kristl J., Šmid-Kobar J. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm. 1998, 48:257-267.
57. Lippacher A., Müller R.H., Mäder K. Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int. J. Pharm. 2000, 196:227-230.
58. Zur Mühlen A., Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 1998, 53:552-555.
59. Zur Mühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - Drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.
60. Lander R., Manger W., Scouloudis M., Ku A., Davis C., Lee A. Gaulin homogenization: a mechanistic study. Biotechnol. Prog. 2000, 16:80-85.
61. Jahnke S. The theory of high pressure homogenization. Emulsions and nanosuspensions for the formulation of poorly soluble drugs 1998, 177-200. Medpharm Scientific Publishers, Stuttgart. R.H. Müller, S. Benita, B. Böhm (Eds.).
62. Siekmann B., Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination. Pharm. Pharmacol. Lett. 1994, 3:194-197.
63. Bunjes H., Siekmann B., Westesen K. Emulsions of supercooled melts - a novel drug delivery system. Submicron Emulsions in Drug Targeting and Delivery 1998, 175-204. Harwood Academic Publishers, Amsterdam. S. Benita (Ed.).
64. A. Zur Mühlen, Feste Lipid-Nanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und mechanismen, Ph.D. Thesis, Free University of Berlin, 1996.
65. Siekmann B., Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur. J. Pharm. Biopharm. 1996, 43:104-109.
66. Moulik S.P., Paul B.K. Structure, dynamics and transport properties of microemulsions. Adv. Coll. Interf. Sci. 1998, 78:99-195.
67. Gasco M.R. Solid lipid nanospheres from warm micro-emulsions. Pharm. Tech. Eur. 1997, 9:52-58.
68. Boltri L., Canal T., Esposito P.A., Carli F. Lipid nanoparticles: Evaluation of some critical formulation parameters. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1993, 20:346-347.
69. De Labouret A., Thioune O., Fessi H., Devissaguet J.P., Puisieux F. Application of an original process for obtaining colloidal dispersions of some coating polymers. Preparation, characterization, industrial scaling up. Drug Dev. Ind. Pharm. 1995, 21:229-241.
70. Cavalli R., Marengo E., Rodriguez L., Gasco M.R. Effect of some experimental factors on the production process of solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 1996, 43:110-115.
71. Gasco M.R., Morel S., Carpigno R. Optimization of the incorporation of desoxycortisone acetate in lipospheres. Eur. J. Pharm. Biopharm. 1992, 38:7-10.
72. C. Schwarz, Feste Lipidnanopartikel: Herstellung, Charakterisierung, Arzneistoffinkorporation und -freisetzung, Sterilisation und Lyophilisation, Ph.D. Thesis, Free University of Berlin, 1995.
73. Phipps L.W. The High Pressure Dairy Homogenizer 1985, 44-78. College of Estate Management, Reading.
74. Cavalli R., Caputo O., Marengo E., Pattarino F., Gasco M.R. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie 1998, 53:392-396.
75. Sculier J.P., Coune A., Brassine C., Laduron C., Atassi G., Ruysschert G.M., Fruhling J. Intravenous infusion of high doses of liposomes containing NSC 251635, a water insoluble cytostatic agent. A pilot study with pharmacokinetic data. J. Clin. Oncol. 1986, 4:789-797.
76. Zuidam N.J., Lee S.S.L., Crommelin D.J.A. Sterilization of liposomes by heat treatment. Pharm. Res. 1992, 10:1591-1596.
77. Lukyanov A.N., Torchilin V.P. Autoclaving of liposomes. J. Microencapsul. 1994, 11:669-672.
78. Schwarz C., Mehnert W. Sterilization of drug-free and tetracaine-loaded solid lipid nanoparticles (SLN). Proc. 1st World Meeting APGI/APV, Budapest 1995, 485-486.
79. Schwarz C., Freitas C., Mehnert W., Müller R.H. Sterilization and physical stability of drug-free and etomidate-loaded solid lipid nanoparticles. Proc. Intern. Symp. Control. Rel. Bioct. Mater. 1995, 22:766-767.
80. Liedtke S., Zimmermann E., Müller R.H., Mäder K. Physical characterisation of solid lipid nanoparticles (SLN™). Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1999, 26:599-600.
81. Müller R.H. Colloidal carriers for controlled drug delivery and targeting 1991, 138-144. Wissenschaftliche Verlagsgesellschaft/CRC Press, Stuttgart/Boca Raton.
82. J.S. Lucks, Parenterale Fettemulsionen als Arzneistoffträger - Herstellung, Charakterisierung und Stabilität, Ph.D. Thesis, Christian Albrechts Universität Kiel, 1993.
83. C. Freitas, Feste Lipid-Nanopartikel (SLN): Mechanismen der physikalischen Destabilisierung und Stabilisierung, Ph.D. Thesis, Free University of Berlin, 1998.
84. Mori H. Solidification problems in preparation of fats. Crystallization and Polymorphism of Fats and Fatty Acids 1988, 423-442. Marcel Dekker Inc., New York, Basel. N. Garti, K. Sato (Eds.).
85. Larsson K., Quinn P.J. Physical properties: structural and physical characteristics. The Lipid Handbook 1994, 401-457. Chapmann and Hall, London, New York. 2nd Edition. F.D. Gunstone, J.L. Harwood, F.B. Padley (Eds.).
86. Cavalli R., Caputo O., Carlotti M.E., Trotta M., Scarnecchia C., Gasco M.R. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 1997, 148:47-54.
87. Heiati H., Tawashi R., Phillips N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilisation. J. Microencapsul. 1998, 15:173-184.
88. Rupprecht H. Physikalisch-chemische Grundlagen der Gefriertrocknung. Lyophilisation. Paperback APV, Band 35 1993, 13-38. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart. D. Essig, R. Oschmann (Eds.).
89. Pikal M.J., Shah S., Roy M.L., Putman R. The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. Int. J. Pharm. 1990, 60:203-217.
90. Crowe L.M., Crowe J.H. Stabilization of dry liposomes by carbohydrates. Dev. Biol. Stand. 1992, 74:285-294.
91. Crowe L.M., Womersley C., Crowe J.H., Reid D., Appel L., Rudolph A. Prevention of fusion and leakage in freeze-dried liposomes by carbohydrates. Biochim. Biophys. Acta 1986, 861:131-140.
92. Doebbler G.F. Cryoprotective compounds. Cryobiology 1966, 3:2-11.
93. Bensouda Y., Cavé G., Seiller M., Puisieux Fr. Freeze-drying of emulsions - influence of congealing on granulometry - research of a cryoprotectant agent. Pharm. Acta Helv. 1989, 64:40-44.
94. Madden T., Bally M., Hope M., Cullis P., Schieren H., Janoff A. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim. Biophys. Acta 1985, 817:67-74.
95. Strauss G., Schurtenberger P., Hauser H. The interaction of saccharides with lipid bilayer vesicles: stabilization during freeze-thawing and freeze-drying. Biochim. Biophys. Acta 1986, 858:169-180.
96. Ausborn M., Nuhn P., Schreier H. Stabilization of liposomes by freeze-thaw and lyophilization techniques: problems and opportunities. Eur. J. Pharm. Biopharm. 1992, 38:133-139.
97. Hauser H., Strauss G. Stabilization of small, unilamellar phospholipid vesicles by sucrose during freezing and dehydration. Adv. Exp. Med. Biol. 1988, 238:71-80.
98. Vemuri S., Yu C.D., DeGroot J., Wangsatornthnakum V., Venkataram S. Effect of sugars on freeze-thaw and lyophilization of liposomes. Drug Dev. Ind. Pharm. 1991, 17:327-348.
99. Strauss G. Freezing and thawing of liposomes suspensions. Liposome Technology, Preparation of Liposomes 1984, Vol. I:197-219. CRC Press, Boca Raton. G. Gregoriadis (Ed.).
100. Shulkin P., Seltzer S., Davis M., Adams D. Lyophilized liposomes: a new method for long-term vesicular storage. J. Microencapsul. 1984, 1:73-80.
101. Mobley W.C., Schreier H. Phase transition temperature reduction and glass transformation in dehydroprotected lyophilized liposomes. J. Controlled Rel. 1994, 31:73-87.
102. Schwarz C., Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparicles. Int. J. Pharm. 1997, 157:171-179.
103. Crowe L.M., Crowe J.H., Rudolph A., Womersley C., Appel L. Preservation of freeze-dried liposomes by trehalose. Arch. Biochem. Biophys. 1985, 242:240-247.
104. Siekmann B., Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. II. Physicochemical characterization and lyophilisation. Pharm. Pharmacol. Lett. 1994, 3:225-228.
105. Zimmermann E., Müller R.H., Mäder K. Influence of different parameters on reconstitution of lyophilized SLN. Int. J. Pharm. 2000, 196:211-213.
106. Freitas C., Müller R.H. Spray-drying of solid lipid nanoparticles (SLN™). Eur. J. Pharm. Biopharm. 1998, 46:145-151.
107. Laggner P. X-ray diffraction of lipids. Spectral Properties of Lipids 1999, 327-367. Sheffield Academic Press, Sheffield. R.J. Hamilton, J. Cast (Eds.).
108. Sato K. Crystallization of fats and fatty acids. Crystallization and Polymorphism of Fats and Fatty Acids 1988, 227-266. Marcel Dekker Inc, New York, Basel. N. Garti, K. Sato (Eds.).
109. Drake B., Prater C.B., Weisenhorn A.L., Gould S.A.C., Albrecht T.R., Quate C.F., Cannell D.S., Hansma H.G., Hansma P.K. Imaging crystals polymers and processes in water with the AFM. Science 1989, 243:1586-1589.
110. Häberle W., Hörber J.K.H., Ohnesorge F., Smith D.P.E., Binnig G. In situ investigations of single living cells infected by viruses. Ultramicroscopy 1992, 1161:42-44.
111. Shakesheff K.M., Davies M.C., Domb A., Glasbey T.O., Jackson D.E., Heller J., Roberts C.J., Shard A.G., Tendler S.J.B., Williams P.M. Visualizing the degradation of polymer surfaces with an Atomic Force Microscope. Proc. Intern. Symp. Control. Rel. Bioact. Mat. 1994, 21:1343-1344.
112. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
113. Meyer E., Heinzelmann H. Scanning force microscopy. Surface Sciences 28 1992, 99-149. Springer Verlag, Berlin, New York. R. Wiesendanger, H.J. Güntherodt (Eds.).
114. Kirby A.R., Gunning A.P., Morris V.J. Imaging xanthum gum by atomic force microscopy. Carbohydr. Res. 1995, 267:161-166.
115. Zur Mühlen A., Zur Mühlen E., Niehus H., Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res. 1996, 13:1411-1416.
116. Dingler A., Blum R.P., Niehus H., Müller R.H., Gohla S. Solid lipid nanoparticles (SLN™/Lipopearls™) - a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J. Microencapsul. 1999, 16:751-767.
117. A. Dingler, Feste Lipid-Nanopartikel als kolloidale Wirkstoffträgersysteme zur dermalen Applikation, Ph.D. Thesis, Free University of Berlin, 1998.
118. Westesen K., Siekmann B., Koch M.H.J. Investigations on the physical state of lipid nanoparticles by synchroton radiation X-ray diffraction. Int. J. Pharm. 1993, 93:189-199.
119. Anger S., Caldwell K.D., Niehus H., Müller R.H. High resolution size determination of 20nm colloidal gold particles by SedFFF. Pharm. Res. 1999, 16:1743-1747.
120. Anger S., Caldwell K.D., Müller R.H. Charakterisierung von makromolekülen, kolloiden und partikeln mit der field flow fractionation. Pharm. Ind. 2000, 62:150-156.
121. Anger S., Mehnert W., Caldwell K.D., Müller R.H. High resolution determination of adsorption layer mass on particles by sedimentation field-flow fractionation. Proc. 2nd World Meeting APGI/APV, Paris 1998, 643-644.
122. Anger S., Caldwell K.D., Mehnert W., Müller R.H. Coating of nanoparticles: analysis of adsorption using sedimentation field-flow fractionation (SdFFF). Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1999, 26:599-600.
123. Müller R.H. Zetapotential und Partikelladung in der Laborpraxis - Einführung in die Theorie, praktische Meßdurchführung, Dateninterpretation 1996, Wissenschaftliche Verlagsgesellschaft, Stuttgart.
124. Westesen K., Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix?. Int. J. Pharm. 1995, 115:129-131.
125. Kobayashi M. Vibrational spectroscopic aspects of polymorphism and phase transition of fats and fatty acids. Crystallization and Polymorphism of Fats and Fatty Acids 1988, 139-188. Marcel Dekker Inc, New York, Basel. N. Garti, K. Sato (Eds.).
126. V. Jenning, Feste Lipid Nanopartikel als Trägersystem für die dermale Applikation von Retinol, Ph.D. Thesis, Free University of Berlin, 1999.
127. Zimmermann E., Liedtke S., Müller R.H., Mäder K. H-NMR as a method to characterize colloidal carrier systems. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1999, 26:595-596.
128. H. Weyers, Feste Lipid Nanopartikel (SLN) für die gewebsspezifische Arzneistoffapplikation - Herstellung und Charakterisierung oberflächenmodifizierter Formulierungen, Ph.D. Thesis, Free University of Berlin, 1995.
129. Almeida A.J., Runge S., Müller R.H. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int. J. Pharm. 1997, 149:255-265.
130. Boistelle R. Fundamentals of nucleation and crystal growth. Crystallization and Polymorphism of Fats and Fatty Acids 1988, 189-226. Marcel Dekker Inc, New York, Basel. N. Garti, K. Sato (Eds.).
131. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Controlled Rel. 2000, 66:115-126.
132. Unruh T., Bunjes H., Westesen K., Koch M.H.J. Observation of size dependent melting in lipid nanoparticles. J. Phys. Chem. B 1999, 103:10373-10377.
133. Siekmann B., Westesen K. Electron-microscopic characterization of melt-homogenised solid lipid nanoparticles. Eur. J. Pharm. Sci. 1994, 2:190.
134. Siekmann B., Westesen K. Thermoanalysis of the recrystallization of melt-homogenized glyceride nanoparticles. Colloids and surfaces B: Biointerfaces 1994, 3:159-175.
135. Westesen K., Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int. J. Pharm. 1997, 151:35-45.
136. Freitas C., Müller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int. J. Pharm. 1998, 168:221-229.
137. Freitas C., Müller R.H. Stability determination of solid lipid nanoparticles (SLN™) in aqueous dispersion after addition of electrolyte. J. Microencapsul. 1999, 16:59-71.
138. Müller R.H., Heinemann S. Fat emulsions for parenteral nutrition. III. Lipofundin MCT/LCT regimens for parenteral nutrition (TPN) with low electrolyte load. Int. J. Pharm. 1994, 101:175-189.
139. Bunjes H., Westesen K., Koch M.H.J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 1996, 129:159-173.
140. Freitas C., Müller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
141. Yoshino H., Kobayashi M., Samejima M. Influence of the fatty acid composition on the properties and polymorphic transition of fatty suppository bases. Chem. Pharm. Bull. 1983, 31:237-246.
142. Garti N. Effects of surfactants on crystallization and polymorhpic transformation of fats and fatty acids. Crystallization and Polymorphism of Fats and Fatty Acids 1988, 267-304. Marcel Dekker Inc, New York, Basel. N. Garti, K. Sato (Eds.).
143. Siekmann B., Westesen K. Submicron lipid suspensions (solid lipid nanoparticles) versus lipid nanoemulsions: similarities and differences. Submicron Emulsions in Drug Targeting and Delivery 1998, 205-218. Harwood Academic Publishers, Amsterdam. S. Benita (Ed.).
144. Stoye I., Schröder K., Müller-Goymann C.C. Transformation of liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - Physico-chemical characterization and influence on drug permeation through the excised human stratum corneum. Eur. J. Pharm. Biopharm. 1998, 46:191-200.
145. Rapoport N. Effect of Pluronic on the intracellular distribution and intracellular dynamics of a spin-labeled analog of doxorubicin. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1998, 26:1052-1053.
146. Ahlin P., Kristl J., Šentjurc M., Štrancar J., Pecar S. Influence of spin probe structure on its distribution in SLN dispersions. Int. J. Pharm. 2000, 196:241-244.
147. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
148. Westesen K., Bunjes H., Koch H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Controlled Rel. 1997, 48:223-236.
149. Cavalli R., Gasco M.R., Morel S. Behaviour of timolol incorporated in lipospheres in the presence of a series of phosphate esters. S.T.P. Pharma Sci. 1992, 2:514-518.
150. Gasco M.R., Cavalli R., Carlotti M.E. Timolol in lipospheres. Pharmazie 1992, 47:119-121.
151. Cavalli R., Morel S., Gasco M.R., Chetoni P., Saettone M.F. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int. J. Pharm. 1995, 117:243-246.
152. Cavalli R., Peira E., Caputo O., Gasco M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrin. Int. J. Pharm. 1999, 182:59-69.
153. Morel S., Ugazio R., Cavalli R., Gasco M.R. Thymopentin in solid lipid nanoparticles. Int. J. Pharm. 1996, 132:259-261.
154. Morel S., Gasco M.R., Cavalli R. Incorporation in lipospheres of [D-Trp-6]LHRH. Int. J. Pharm. 1994, 105:R1-R3.
155. Morel S., Terreno E., Ugazio E., Aime S., Gasco M.R. NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes. Eur. J. Pharm. Biopharm. 1998, 45:157-163.
156. Heiati H., Tawashi R., Shivers R.R., Phillipps N.C. Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate. Int. J. Pharm. 1997, 146:123-131.
157. Heiati H., Tawashi R., Phillipps N.C. Solid lipid nanoparticles as drug carriers. II. Plasma stability and biodistribution of solid lipid nanoparticles containing the prodrug 3'-azido-3'-deoxythymidine palmitate in mice. Int. J. Pharm. 1998, 174:71-80.
158. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Controlled Rel. 1999, 59:299-307.
159. Yang S., Zhu J., Lu Y., Liang B., Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 1999, 16:751-757.
160. Lukowski G., Pflegel P. Electron diffraction of solid lipid nanoparticles loaded with aciclovir. Pharmazie 1997, 52:642-643.
161. Lukowski G., Werner U., Pflegel P. Investigation of surface and drug release of drug-loaded solid lipid nanoparticles. Proc. 2nd World Meeting APGI/APV, Paris 1998, 573-574.
162. S.A. Runge, Feste Lipidnanopartikel (SLN™) als kolloidaler Arzneistoffträger für die orale Applikation von Ciclosporin A, Ph.D. Thesis, Free University of Berlin, 1998.
163. H. Bunjes, Einflußnahme unterschiedlicher Faktoren auf Struktur und Eigenschaften von Nanopartikeln aus festen Triglyceriden. Ph.D. Thesis, Friedrich-Schiller-Universität Jena, 1998.
164. Ahlin P., Kristl J., Šentjurc M. EPR study of loading capacity and location of spin-labelled lipophilic substance in different SLN. Proc. Int. Symp. Control. Rel. Bioact. Mater. 1998, 25:334-335.
165. K. Mäder, Habilitation Thesis, Humboldt University Berlin, 1998.
166. Olbrich C., Müller R.H. Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures. Int. J. Pharm. 1999, 180:31-39.
167. Metha R.C., Head L.F., Hazrati A.M., Parr M., Rapp R.P., DeLuca P.P. Fat emulsion particle-size distribution in total nutrient admixtures. Am. J. Hosp. Pharm 1992, 49:2749-2755.
168. Puntis J.W., Wilkins K.M., Ball P.A., Rushton D.I., Booth I.W. Hazards of parenteral treatment: do particles count?. Arch. Dis. Child. 1992, 67:1475-1477.
169. Blunk T., Hochstrasser D.F., Müller B.W., Müller R.H. Differential adsorption: Effect of plasma protein adsorption patterns on organ distribution of colloidal drug carriers. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1993, 20:256-257.
170. Müller R.H., Maaßen S., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulozytes. J. Controlled Rel. 1997, 47:261-269.
171. Müller R.H., Maaßen S., Weyhers H., Mehnert W. Phagozytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target. 1996, 4:161-170.
172. Illum L., Davis S.S., Müller R.H., Mak E., West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer-Poloxamine 908. Life Sci. 1987, 40:367-374.
173. Rudt S., Müller R.H. In vitro uptake of polystyrene latex particles and parenteral fat emulsions by human granulocytes. Int. J. Pharm. 1993, 99:1-6.
174. st communication. Pharm. Ind. 1999, 61:462-467.
175. Bocca C., Caputo O., Cavalli R., Gabriel L., Miglietta A., Gasco M.R. Phagozytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm. 1998, 175:185-193.
176. Cavalli R., Bocca C., Miglietta A., Caputo O., Gasco M.R. Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. S.T.P. Pharma Sci. 1999, 9:183-189.
177. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Del. Rev. 1995, 16:141-155.
178. Mosmann T. Rapid colorimetric assay of cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 1983, 65:55-63.
179. Müller R.H., Maaßen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. 1996, 138:85-94.
180. Maaßen S., Schwarz C., Mehnert W., Lucks J.S., Yunis-Specht F., Müller B.W., Müller R.H. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 1993, 20:490-491.
181. Müller R.H., Maaßen S., Weyhers H., Mehnert W. Phagozytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target. 1996, 4:161-170.
182. Borgström B. Importance of phospholipids, pancreatic phospholipase A2, and fatty acid for the digestion of dietary fat. Gastroenterology 1980, 78:954-962.
183. Borgström B., Donner J. The polar interactions between pancreatic lipase, colipase and the triglyceride substrate. FEBS Lett. 1977, 83:23-26.
184. Scow R.O., Olivecorona T. Effect of albumin products formed from chylomicron triacyl-glycerol by lipoprotein lipase in vitro. Biochem. Biophys. Acta 1977, 487:472-486.
185. Müller R.H., Olbrich C. Solid lipid nanoparticles: phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation, 2nd communication. Pharm. Ind. 1999, 61:564-569.
186. Olbrich C., Mehnert W., Müller R.H. In vitro degradation properties of solid lipid nanoparticles. Proc. 2nd World Meeting APGI/APV, Paris 1998, 577-578.
187. Müller R.H., Rühl D., Runge S.A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 1996, 144:115-121.
188. Olbrich C., Mehnert W., Müller R.H. In vitro degradation properties of solid lipid nanoparticles. Proc. 2nd World Meeting APGI/APV, Paris 1998, 627-628.
189. L. Penkler, R.H. Müller, S.A. Runge, V. Ravelli, Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation, WO 99/56733, 1999.
190. Bargoni A., Cavalli R., Caputo O., Fundaro A., Gasco M.R., Zara G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 1998, 15:745-750.
191. Zara G.P., Cavalli R., Fundarò A., Bargoni A., Caputo O., Gasco M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharm. Res. 1999, 44:281-286.
192. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with Polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14:325-328.
193. R.H. Müller, M. Lück, J. Kreuter, Arzneistoffträgerpartikel für die gewebsspezifische Arzneistoffapplikation, German patent, Application No. 197 45 950.1, 1997.
194. R.H. Müller, S. Wissing, K. Mäder. Sunscreens containing UV radiation reflecting or absorbing agents, protecting against harmful UV radiation and reinforcing the natural skin barrier. PCT Int. Appl. (2001), WO 01/03652.
195. Maia C.S., Mehnert W., Schäfer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm. 2000, 196:165-167.